Internal Medicine, Endocrinology, Diabetes, & Metabolism · Dallas, TX
NPI
1790777365
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
3417 Gaston Ave, Suite 980
Dallas, TX, 75246
Phone (469) 800-8020
Groups this clinician bills Medicare through
Medicare paid, 2024
$50K
969 services
Medicare patients, 2024
325
Average age 74
Drug cost, 2024
$3.9M
2,665 prescriptions
Company payments, 2025
$1,113
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Raphaelle D Vallera was code 36415 (venipuncture blood collection), 386 times for 273 patients. In total Raphaelle D Vallera billed 969 services in 11 codes, and Medicare paid $50K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-02-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 386 | 273 | $8.63 | $3,331 |
| 99214 Office E&M - Established | Office | 379 | 273 | $83.31 | $32K |
| 99215 Office E&M - Established | Office | 110 | 86 | $117.12 | $13K |
| 95251 Test - Miscellaneous | Office | 71 | 45 | $25.73 | $1,827 |
By year: 2022 $57K for 1,076 services; 2023 $63K for 1,124 services; 2024 $50K for 969 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 386 | 273 | $8.63 | $3,331 |
Medicare prescription drug claims, 2024
In 2024, the drug Raphaelle D Vallera prescribed most often to Medicare patients was Unithroid (Levothyroxine Sodium), with 555 prescriptions and refills. In total Raphaelle D Vallera wrote 2,665 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Unithroid Levothyroxine Sodium | 555 | 1,455 | 146 | $25K |
| Jardiance Empagliflozin | 268 | 498 | 52 | $277K |
| Synthroid Levothyroxine Sodium | 194 | 502 | 50 | $22K |
| Ozempic Semaglutide | 144 | 235 | 30 | $212K |
| Metformin Hcl Generic | 103 | 259 | 29 | $1,187 |
| Trulicity Dulaglutide | 102 | 171 | 24 | $166K |
| Metformin Hcl Er Metformin Hcl | 86 | 239 | 23 | $942 |
| Rosuvastatin Calcium Generic | 67 | 180 | 20 | $679 |
| Atorvastatin Calcium Generic | 63 | 181 | 17 | $482 |
| Indapamide Generic | 62 | 138 | 16 | $521 |
| Tirosint Levothyroxine Sodium | 48 | 103 | Under 11 | $14K |
| Levothyroxine Sodium Generic | 47 | 119 | 16 | $1,976 |
| Lisinopril Generic | 46 | 138 | 15 | $232 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 43 | 103 | 13 | $4,450 |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | 36 | 91 | Under 11 | $20K |
Brand drugs: 1,722 claims; generic drugs: 854 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Raphaelle D Vallera $1,113 ($1,113 in general payments such as food, travel and fees) from 24 companies. The largest payer was Corcept Therapeutics with $218.
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics CORT | 10 | $218 |
| Amgen Inc. AMGN | 7 | $134 |
| Amneal Pharmaceuticals LLC AMRX | 3 | $81.76 |
| Sanofi-Aventis U.S. LLC SNY | 2 | $73.32 |
| Xeris Pharmaceuticals, Inc. | 3 | $55.15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $51.79 |
| Beta Bionics, Inc. BBNX | 2 | $50.08 |
| Abbott Laboratories ABT | 2 | $48.56 |
| IBSA Pharma Inc. | 3 | $45.35 |
| Sequel Med Tech, LLC | 1 | $39.19 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.